{
    "root": "620f749d-59d2-46fb-befa-7a1356bff383",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lorbrena",
    "value": "20250501",
    "ingredients": [
        {
            "name": "LORLATINIB",
            "code": "OSP71S83EU"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "lorbrena® indicated treatment adult patients metastatic non-small cell lung cancer ( nsclc ) whose tumors anaplastic lymphoma kinase ( alk ) -positive detected fda-approved test .",
    "contraindications": "recommended : 100 mg orally daily . ( 2.2 ) severe renal impairment : 75 mg orally daily . ( 2.8 , 8.7 , 12.3 )",
    "warningsAndPrecautions": "table 11 describes available strengths package configurations lorbrena : table 11 lorbrena tablets package configuration strength ( mg ) ndc description 30 count bottle child-resistant closure 25 0069-0227-01 8 mm round , tan , immediate release film-coated , debossed `` pfizer `` one side `` 25 `` `` lln `` side 120 count bottle child-resistant closure 25 0069-0227-03 8 mm round , tan , immediate release film-coated , debossed “ pfizer ” one side “ 25 ” “ lln ” side 30 count bottle child-resistant closure 100 0069-0231-01 8.5 mm × 17 mm oval , lavender , immediate release , film-coated , debossed `` pfizer `` one side `` lln 100 `` side",
    "adverseReactions": "lorbrena contraindicated patients taking strong cyp3a inducers , due potential serious hepatotoxicity [ ( 5.1 ) ] .",
    "indications_original": "LORBRENA® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.",
    "contraindications_original": "Recommended dosage: 100 mg orally once daily. ( 2.2 ) Severe Renal Impairment: 75 mg orally once daily. ( 2.8 , 8.7 , 12.3 )",
    "warningsAndPrecautions_original": "Table 11 describes the available strengths and package configurations for LORBRENA:\n                  \n                     Table 11 \tLORBRENA Tablets\n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Package Configuration\n                           \n                           \n                              Strength\n                              \n                               (mg)\n                           \n                           \n                              NDC\n                           \n                           \n                              Description\n                           \n                        \n                     \n                     \n                        \n                           \n                              30 count bottle with a child-resistant closure\n                           \n                           \n                              25\n                           \n                           \n                              0069-0227-01\n                           \n                           \n                              8 mm round, tan, immediate release film-coated, debossed with \"Pfizer\" on one side and \"25\" and \"LLN\" on the other side\n                           \n                        \n                        \n                           \n                              120 count bottle with a child-resistant closure\n                           \n                           \n                              25\n                           \n                           \n                              0069-0227-03\n                           \n                           \n                              8 mm round, tan, immediate release film-coated, debossed with “Pfizer” on one side and “25” and “LLN” on the other side\n                           \n                        \n                        \n                           \n                              30 count bottle with a child-resistant closure\n                           \n                           \n                              100\n                           \n                           \n                              0069-0231-01\n                           \n                           \n                              8.5 mm × 17 mm oval, lavender, immediate release, film-coated, debossed with \"Pfizer\" on one side and \"LLN 100\" on the other side",
    "adverseReactions_original": "LORBRENA is contraindicated in patients taking strong CYP3A inducers, due to the potential for serious hepatotoxicity [see Warnings and Precautions (5.1)]."
}